Clene Reports Q1 2026 Financial Results with Significant Cash Position
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CLNN?
Source: seekingalpha
- Financial Performance: Clene reported a Q1 2026 GAAP EPS of -$0.69 with revenue of only $0.01 million, indicating significant challenges in revenue generation that may impact investor confidence.
- Cash Position: As of March 31, 2026, Clene's cash and cash equivalents totaled $5.9 million, an increase from $5.2 million as of December 31, 2025, reflecting improvements in the company's cash management.
- Funding Outlook: Clene expects that its resources, including $7.0 million in gross proceeds from its May 2026 registered direct offering, will provide operational runway into Q4 2026, demonstrating proactive financing efforts.
- Future Prospects: With potential future warrant exercises tied to FDA NDA acceptance amounting to approximately $7.0 million, Clene's cash runway is projected to extend into 2027, enhancing the company's growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLNN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLNN
Wall Street analysts forecast CLNN stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.500
Low
30.00
Averages
30.40
High
31.00
Current: 6.500
Low
30.00
Averages
30.40
High
31.00
About CLNN
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clene Reports Q1 2026 Financial Results with Significant Cash Position
- Financial Performance: Clene reported a Q1 2026 GAAP EPS of -$0.69 with revenue of only $0.01 million, indicating significant challenges in revenue generation that may impact investor confidence.
- Cash Position: As of March 31, 2026, Clene's cash and cash equivalents totaled $5.9 million, an increase from $5.2 million as of December 31, 2025, reflecting improvements in the company's cash management.
- Funding Outlook: Clene expects that its resources, including $7.0 million in gross proceeds from its May 2026 registered direct offering, will provide operational runway into Q4 2026, demonstrating proactive financing efforts.
- Future Prospects: With potential future warrant exercises tied to FDA NDA acceptance amounting to approximately $7.0 million, Clene's cash runway is projected to extend into 2027, enhancing the company's growth potential.
See More
Clene Prices $7 Million Direct Stock Offering
- Offering Details: Clene and its wholly owned subsidiary, Clene Nanomedicine, announced a direct offering of 1 million shares at $7.00 per share to a single investor, with gross proceeds expected to be around $7 million, indicating the company's active engagement in capital markets.
- Use of Proceeds: The net proceeds from this offering will be utilized alongside existing cash for general corporate purposes, reflecting a prudent financial strategy aimed at supporting future operations and growth.
- Expected Closing Date: The offering is anticipated to close on or about May 6, 2026, showcasing the company's proactive management of future liquidity to ensure ongoing business operations.
- Market Reaction Outlook: While this offering may dilute existing shareholders' stakes, the company strengthens its capital base through this move, potentially providing greater growth opportunities for investors in the future.
See More
Clene Plans NDA Submission by Q3 2026 for ALS Treatment
- Positive FDA Feedback: Clene's experimental ALS treatment CNM-Au8 received encouraging feedback from the FDA, which indicated that data on the NfL biomarker may support an accelerated New Drug Application, highlighting the drug's potential in nerve damage and positively impacting Clene's market outlook.
- Strong Safety Profile: CNM-Au8 has demonstrated a favorable safety profile with no serious treatment-related side effects reported, which not only boosts investor confidence in the drug but also lays a solid foundation for future clinical trials.
- Strong Market Reaction: Clene's shares surged over 8% on Monday, reflecting investor optimism following the FDA news, and reached their highest levels in 2026, indicating strong market interest in the company's future developments.
- Retail Investor Sentiment Shift: On Stocktwits, retail investor sentiment for Clene shifted from 'bullish' to 'extremely bullish', accompanied by extremely high message volumes, indicating increased confidence in the likelihood of NDA acceptance, although some investors remain skeptical about its true significance.
See More
Clene Plans NDA Submission for ALS Drug CNM-Au8
- FDA Support for NDA: The FDA indicated that Clene's proposed data for CNM-Au8 may support its New Drug Application (NDA) submission under the accelerated approval pathway, presenting a significant opportunity for the company in ALS treatment advancement.
- Biomarker Data Importance: The FDA emphasized that changes in the neurofilament light (NfL) biomarker could serve as a reasonably likely surrogate endpoint, requiring Clene to demonstrate the connection between NfL changes and clinical benefits to strengthen its NDA.
- Clear Submission Timeline: Clene plans to submit its NDA in the third quarter of 2026, marking a crucial milestone in the development of its ALS drug and potentially accelerating patient access to new therapies.
- Clinical Trial Support: The NDA submission will be supported by data from the Phase 2 HEALEY ALS Platform Trial and RESCUE-ALS Trial, which indicate that reductions in NfL levels are associated with longer survival, further enhancing the market potential of CNM-Au8.
See More
Clene Reports FY 2025 Financial Results with Significant Losses
- Earnings Report: Clene's FY 2025 GAAP EPS stands at -$2.65, indicating significant challenges in profitability that could undermine investor confidence and future financing capabilities.
- Revenue Performance: The company reported revenue of only $0.2 million, falling far short of market expectations, suggesting insufficient market acceptance of its products or services, which may lead to slowed future growth.
- Liquidity Position: As of December 31, 2025, Clene's cash and cash equivalents totaled $5.2 million, a substantial decrease from $12.2 million in 2024, highlighting pressures in cash management and operational sustainability.
- Financing Initiative: Clene announced a registered direct offering of over $28 million, aimed at strengthening its capital base, although this may dilute existing shareholders' stakes and impact shareholder value.
See More
Clene Inc. Outlines Key Milestones for 2026
- Sufficient Funding: Clene Inc. completed an oversubscribed registered direct offering of over $28 million, with an initial tranche of over $6 million expected to fund operations into the fourth quarter of 2026, ensuring capital availability ahead of a potential New Drug Application (NDA) acceptance decision.
- FDA Meeting Scheduled: The company plans an in-person Type C meeting with the FDA by the end of Q1 2026 to discuss data submitted for CNM-Au8 in late 2025, which is expected to provide critical feedback for the NDA submission and accelerate the approval process.
- Clinical Data Support: CNM-Au8 has demonstrated significant survival benefits and declines in biomarkers in ALS patients, supporting its candidacy for accelerated approval, with ongoing discussions with the FDA indicating alignment with regulatory expectations.
- Upcoming Trial Plans: Clene intends to initiate the confirmatory Phase 3 RESTORE-ALS trial later in 2026 to validate the survival benefits observed with CNM-Au8, meeting FDA requirements for the accelerated approval pathway and further solidifying its position in neurodegenerative disease treatment.
See More
Clene Reports Q1 2026 Financial Results with Significant Cash Position
- Financial Performance: Clene reported a Q1 2026 GAAP EPS of -$0.69 with revenue of only $0.01 million, indicating significant challenges in revenue generation that may impact investor confidence.
- Cash Position: As of March 31, 2026, Clene's cash and cash equivalents totaled $5.9 million, an increase from $5.2 million as of December 31, 2025, reflecting improvements in the company's cash management.
- Funding Outlook: Clene expects that its resources, including $7.0 million in gross proceeds from its May 2026 registered direct offering, will provide operational runway into Q4 2026, demonstrating proactive financing efforts.
- Future Prospects: With potential future warrant exercises tied to FDA NDA acceptance amounting to approximately $7.0 million, Clene's cash runway is projected to extend into 2027, enhancing the company's growth potential.
See More
Clene Prices $7 Million Direct Stock Offering
- Offering Details: Clene and its wholly owned subsidiary, Clene Nanomedicine, announced a direct offering of 1 million shares at $7.00 per share to a single investor, with gross proceeds expected to be around $7 million, indicating the company's active engagement in capital markets.
- Use of Proceeds: The net proceeds from this offering will be utilized alongside existing cash for general corporate purposes, reflecting a prudent financial strategy aimed at supporting future operations and growth.
- Expected Closing Date: The offering is anticipated to close on or about May 6, 2026, showcasing the company's proactive management of future liquidity to ensure ongoing business operations.
- Market Reaction Outlook: While this offering may dilute existing shareholders' stakes, the company strengthens its capital base through this move, potentially providing greater growth opportunities for investors in the future.
See More
Clene Plans NDA Submission by Q3 2026 for ALS Treatment
- Positive FDA Feedback: Clene's experimental ALS treatment CNM-Au8 received encouraging feedback from the FDA, which indicated that data on the NfL biomarker may support an accelerated New Drug Application, highlighting the drug's potential in nerve damage and positively impacting Clene's market outlook.
- Strong Safety Profile: CNM-Au8 has demonstrated a favorable safety profile with no serious treatment-related side effects reported, which not only boosts investor confidence in the drug but also lays a solid foundation for future clinical trials.
- Strong Market Reaction: Clene's shares surged over 8% on Monday, reflecting investor optimism following the FDA news, and reached their highest levels in 2026, indicating strong market interest in the company's future developments.
- Retail Investor Sentiment Shift: On Stocktwits, retail investor sentiment for Clene shifted from 'bullish' to 'extremely bullish', accompanied by extremely high message volumes, indicating increased confidence in the likelihood of NDA acceptance, although some investors remain skeptical about its true significance.
See More
Clene Plans NDA Submission for ALS Drug CNM-Au8
- FDA Support for NDA: The FDA indicated that Clene's proposed data for CNM-Au8 may support its New Drug Application (NDA) submission under the accelerated approval pathway, presenting a significant opportunity for the company in ALS treatment advancement.
- Biomarker Data Importance: The FDA emphasized that changes in the neurofilament light (NfL) biomarker could serve as a reasonably likely surrogate endpoint, requiring Clene to demonstrate the connection between NfL changes and clinical benefits to strengthen its NDA.
- Clear Submission Timeline: Clene plans to submit its NDA in the third quarter of 2026, marking a crucial milestone in the development of its ALS drug and potentially accelerating patient access to new therapies.
- Clinical Trial Support: The NDA submission will be supported by data from the Phase 2 HEALEY ALS Platform Trial and RESCUE-ALS Trial, which indicate that reductions in NfL levels are associated with longer survival, further enhancing the market potential of CNM-Au8.
See More
Clene Reports FY 2025 Financial Results with Significant Losses
- Earnings Report: Clene's FY 2025 GAAP EPS stands at -$2.65, indicating significant challenges in profitability that could undermine investor confidence and future financing capabilities.
- Revenue Performance: The company reported revenue of only $0.2 million, falling far short of market expectations, suggesting insufficient market acceptance of its products or services, which may lead to slowed future growth.
- Liquidity Position: As of December 31, 2025, Clene's cash and cash equivalents totaled $5.2 million, a substantial decrease from $12.2 million in 2024, highlighting pressures in cash management and operational sustainability.
- Financing Initiative: Clene announced a registered direct offering of over $28 million, aimed at strengthening its capital base, although this may dilute existing shareholders' stakes and impact shareholder value.
See More
Clene Inc. Outlines Key Milestones for 2026
- Sufficient Funding: Clene Inc. completed an oversubscribed registered direct offering of over $28 million, with an initial tranche of over $6 million expected to fund operations into the fourth quarter of 2026, ensuring capital availability ahead of a potential New Drug Application (NDA) acceptance decision.
- FDA Meeting Scheduled: The company plans an in-person Type C meeting with the FDA by the end of Q1 2026 to discuss data submitted for CNM-Au8 in late 2025, which is expected to provide critical feedback for the NDA submission and accelerate the approval process.
- Clinical Data Support: CNM-Au8 has demonstrated significant survival benefits and declines in biomarkers in ALS patients, supporting its candidacy for accelerated approval, with ongoing discussions with the FDA indicating alignment with regulatory expectations.
- Upcoming Trial Plans: Clene intends to initiate the confirmatory Phase 3 RESTORE-ALS trial later in 2026 to validate the survival benefits observed with CNM-Au8, meeting FDA requirements for the accelerated approval pathway and further solidifying its position in neurodegenerative disease treatment.
See More
